Drug Target Review
APRIL 7, 2025
PoLiPa technology Domainex’s Polymer Lipid Particle (PoLiPa) technology offers a versatile, detergent-free platform for the rapid, high-purity preparation of membrane proteins like GPCRs, ion channels and solute carriers, enabling assay development for these challenging targets.
Drug Target Review
JUNE 15, 2023
His aims are to seek out the emerging therapeutic opportunities that RNA targets present and to develop effective methods to interrogate the underlying biology. Sam focuses on the application of innovative assay development strategies to enable to interrogation of complex targets.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zobio
FEBRUARY 8, 2024
ZoBio was represented by Pim de Vink (Scientist, Assay Development and Screening) who presented poster Screening for Fragment Molecular. The meeting focused on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programs.
Zobio
FEBRUARY 8, 2024
ZoBio was represented by Pim de Vink (Scientist, Assay Development and Screening) who presented poster Screening for Fragment Molecular. The meeting focused on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programs.
Broad Institute
JUNE 30, 2023
LipocyteProfiler builds on the concept of image-based profiling that was first introduced in the context of morphology mapping by Cell Painting, a high-content imaging assay developed by Broad institute scientist and Imaging Platform senior director Anne Carpenter.
Sygnature Discovery
JANUARY 17, 2023
About SB Drug Discovery SB Drug Discovery is an industry leader in specialist contract research, providing critical data for novel drug development through cell line generation, assay development and compound screening services. SB is based in Glasgow and employs 55 people.
The Pharma Data
MARCH 20, 2021
Patients with COVID-19 present with upper respiratory infections that can result in a number of complications particularly in patients of advanced age or with co-morbidities. An overview of the genome organization of SARS-CoV-2 is presented in Figure 1A. SARS-CoV-2 is the cause of the current COVID-19 pandemic ( 4 , 5 ).
Expert insights. Personalized for you.
52 
Let's personalize your content